Cutaneous Leishmaniasis
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Nielsen BioSciencesCA - San Diego
1 program1
Leishmania tropica Skin Test AntigenPhase 21 trial
Active Trials
Allergy TherapeuticsUK - West Sussex
1 programSurveillance for Leishmaniasis Skin Lesions in MaliN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Nielsen BioSciencesLeishmania tropica Skin Test Antigen
Allergy TherapeuticsSurveillance for Leishmaniasis Skin Lesions in Mali
Clinical Trials (2)
Total enrollment: 1,643 patients across 2 trials
Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen
Start: Aug 2008Est. completion: Jan 201050 patients
Phase 2Completed
Surveillance for Leishmaniasis Skin Lesions in Mali
Start: Mar 2006Est. completion: Sep 20121,593 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.